NYSE - Nasdaq Real Time Price USD

Nuvation Bio Inc. (NUVB)

4.1600 -0.0300 (-0.72%)

At close: November 6 at 4:00:02 PM EST

4.1900 +0.0300 (+0.72%)

After hours: November 6 at 6:45:56 PM EST

Trade NUVB on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for NUVB

40m ago Powered by Yahoo Scout

Nuvation Bio delivered $45.0 million in third-quarter revenue, led by continued IBTROZI growth and partner payments. Management also reported encouraging safusidenib data, expanded its Phase 3 program, and maintained a cash balance supporting its current operating plan.

Previous Close 4.1900
Open 4.2100
Bid 4.1900 x 2210000
Ask 4.1400 x 2250000
Day's Range 3.9800 - 4.3290
52 Week Range 3.9800 - 9.7500
Volume 5,328,011
Avg. Volume 5,376,265
Market Cap (intraday) 1.469B
Beta (5Y Monthly) 1.73
PE Ratio (TTM) --
EPS (TTM) -0.3900
Earnings Date Nov 4, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 13.00
Zacks Rating Neutral

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

www.nuvationbio.com

310

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NUVB

53.57%

S&P 500 (^GSPC)

7.76%

1-Year Return

NUVB

17.13%

S&P 500 (^GSPC)

9.77%

3-Year Return

NUVB

215.15%

S&P 500 (^GSPC)

68.96%

5-Year Return

NUVB

54.78%

S&P 500 (^GSPC)

57.04%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q3 FY26

Revenue 44.95M

Earnings -41.9M

Profit Margin -93.21%

FY25

FY26

-50M

50M

-150.0%

-100.0%

-50.0%

0.0%

Analyst Price Targets

7.00

13.00 Average

4.1600 Current

21.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 11/5/2026

Analyst RBC Capital

Rating Action Maintains

Rating Outperform

Price Action Lowers

Price Target 20 -> 17

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

-67.38%
Return on Assets (ttm)

-11.18%
Return on Equity (ttm)

-49.09%
Revenue (ttm)

201.73M
Net Income Avi to Common (ttm)

-135.93M
Diluted EPS (ttm)

-0.3900

Balance Sheet and Cash Flow

Total Cash (mrq)

663.37M
Total Debt/Equity (mrq)

205.34%
Levered Free Cash Flow (ttm)

-76.06M

LYEL Lyell Immunopharma, Inc.

14.86 -0.93%

TSHA Taysha Gene Therapies, Inc.

4.3300 +5.87%

STOK Stoke Therapeutics, Inc.

26.54 +4.33%

OLMA Olema Pharmaceuticals, Inc.

7.33 +8.43%

ANNX Annexon, Inc.

4.2000 +4.87%

U.S. markets closed

Nuvation Bio Inc. (NUVB)

Trading disclosure

-12.61%

-14.75%

-17.46%

-53.57%

-17.13%

-54.78%

-58.81%

What's happening with NUVB?

Nuvation Bio Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch